Option Care Health, Inc.
NASDAQ•OPCH
CEO: Mr. John C. Rademacher
Sector: Healthcare
Industry: Medical - Care Facilities
Listing Date: 1996-08-15
Option Care Health, Inc. offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders. It also offers treatments to manage the progression of neurological disorders, such as multiple sclerosis, duchenne muscular dystrophy, and other neurological disorder; infusion therapies for bleeding disorders, such as hemophilia and von Willebrand diseases; therapies for women with high-risk pregnancies; and other infusion therapies to treat various conditions, including pain management, chemotherapy, and respiratory medications, as well as nursing services. The company markets its services through patient referrals, including physicians, hospital discharge planners, hospital personnel, health maintenance organizations, and preferred provider organizations. Option Care Health, Inc. is headquartered in Bannockburn, Illinois.
Contact Information
3000 Lakeside Drive, Suite 300N, Bannockburn, IL, 60015, United States
312-940-2443
Market Cap
$4.67B
P/E (TTM)
22.4
49
Dividend Yield
--
52W High
$36.80
52W Low
$24.24
52W Range
Rank44Top 53.8%
3.7
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Weak • 3.7 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025
Financial Dashboard
Q4 2025 Data
Revenue
$1.47B+0.00%
4-Quarter Trend
EPS
$0.37+0.00%
4-Quarter Trend
FCF
$17.43M+0.00%
4-Quarter Trend
2025 Annual Earnings Highlights
Key Highlights
Net Revenue Growth Strong Net Revenue grew $651.3M USD, driven by 13.0% organic growth across acute and chronic therapies in 2025.
Operating Income Increased Operating Income rose $16.1M USD to $337.9M USD, showing operational efficiency gains over prior year results.
Share Repurchase Program Boosted Deployed $310.0M USD for share repurchases in 2025; authorization increased to $1B in January 2026.
Debt Structure Optimized Refinanced First Lien Term Loan via Fourth Amendment, reducing interest margin by 50 basis points; maturity extended.
Risk Factors
Gross Margin Compression Continues Gross margin compressed 1.0 point to 19.3% due to therapy mix; expects $25M to $35M negative impact in 2026.
Payer Dependency and Pricing High dependency on payers (88% revenue); continued pricing pressure and consolidation may limit contract negotiation leverage.
Liquidity Reduced by Outflows Cash decreased $179.9M USD to $232.6M USD due to significant investing and financing outflows impacting liquidity.
Regulatory Compliance Exposure Extensive regulatory environment poses risk of noncompliance penalties, operational disruption, and increased compliance costs.
Outlook
Focus on Strategic Acquisitions Strategy focuses on strategic capital deployment, including tuck-in acquisitions complementing existing operations for growth.
Technology Integration Required Must effectively adopt and integrate evolving technologies like AI to maintain competitive position and client retention.
Workforce Attraction Priority Continued focus on attracting and retaining skilled clinicians amidst regional shortages to ensure quality service delivery.
Capital for Future Growth Expects to use operating cash flow for debt service, capital expenditures, and strategic growth initiatives beyond 12 months.
Peer Comparison
Revenue (TTM)
$11.70B
$5.65B
$2.53B
Gross Margin (Latest Quarter)
2763.6%
111.8%
90.8%
Key Metrics
Symbol | Market Cap | P/E (TTM) | ROE (TTM) | Debt to Assets |
|---|---|---|---|---|
| KYMR | $6.50B | -21.6 | -29.1% | 4.7% |
| CHE | $5.62B | 21.0 | 23.9% | 9.4% |
| LNTH | $5.21B | 22.0 | 20.6% | 30.2% |
Long-Term Trends
Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
3.2%
Moderate Growth
4Q Net Income CAGR
7.8%
Profitability Improving
Cash Flow Stability
75%
Volatile Cash Flow
Deep Research
Next earnings:Apr 29, 2026
EPS:$0.40
|Revenue:$1.41B
Financials
Earnings Calls
Reports
News
Income Statement
Balance Sheet
Cash Flow Statement
Ratios
% Chg.
Income Statement | LTM |
|---|
No Data